Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICARD-Lung: Carfilzomib for AMR in Lung Transplant
NCT02474927Phase 2Completed
- Start
- Nov 2015
- Primary completion
- Nov 2020
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in antibody mediated rejection (AMR). Primary endpoints: Number of Participants With a Decrease in Titer of One or More DSA at Day 42, Number of Participants With a Decrease in DSA Titer at Day 42 and 1 more. Started Nov 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02474927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474927.